The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Flurodex     5-fluoro-1H-pyrimidine-2,4- dione

Synonyms: Neofluor, Adrucil, Onkofluor, Ribofluor, Efudex, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Efudex


Psychiatry related information on Efudex

  • Individual differences in plasma fluorouracil levels, and also in derived pharmacokinetic constants, were considerably less than those reported previously [5].
  • RESULTS: There were 87 patients in the 5-FU and LMWH therapy group and 87 in the placebo group [6].
  • The addition of interferon-alpha gave fever, lethargy, myelosuppression and depression, but did not increase the incidence or severity of 5-FU related toxicities [7].
  • The best response rate, tolerance, and patient compliance with assigned dose were in patients receiving 0.5 ml of 5-FU/epi gel three times a week for 2 weeks [8].
  • A 68-year-old woman, who was treated with 5-fluorouracil (5-FU) intravenous therapy weekly for variable periods following hemicolectomy for adenocarcinoma of the cecum, had at least two well-described episodes of mental confusion, disorientation, and deterioration, in the absence of cerebellar tract signs [9].

High impact information on Efudex


Chemical compound and disease context of Efudex


Biological context of Efudex

  • Targeted disruption of the FDXR gene in human colon cancer cells showed that it was essential for viability, and partial disruption of the gene resulted in decreased sensitivity to 5-FU-induced apoptosis [19].
  • To identify genes downstream of p53 that might mediate these effects, we assessed global patterns of gene expression following 5-FU treatment of isogenic cells differing only in their p53 status [19].
  • In vitro investigations have shown intact p53 to play a critical role executing cell death in response to treatment with cytotoxic drugs like 5-fluorouracil, etoposide and doxorubicin [20].
  • Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer [21].
  • At the maximally tolerated dose, 5'-dFUrd (500 mg/kg/day) and FUra (25-35 mg/kd/day) were equally effective in producing cures when treatments were performed by either continuous iv infusion or iv push [22].

Anatomical context of Efudex


Associations of Efudex with other chemical compounds


Gene context of Efudex


Analytical, diagnostic and therapeutic context of Efudex


  1. Adjuvant therapy for colon cancer. Macdonald, J.S. CA: a cancer journal for clinicians. (1997) [Pubmed]
  2. Moving beyond fluorouracil for colorectal cancer. Mayer, R.J. N. Engl. J. Med. (2000) [Pubmed]
  3. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., Brambilla, C. N. Engl. J. Med. (1995) [Pubmed]
  4. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. Herskovic, A., Martz, K., al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V., Cooper, J., Byhardt, R., Davis, L., Emami, B. N. Engl. J. Med. (1992) [Pubmed]
  5. Pharmacokinetics of fluorouracil in humans. MacMillan, W.E., Wolberg, W.H., Welling, P.G. Cancer Res. (1978) [Pubmed]
  6. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. Asaria, R.H., Kon, C.H., Bunce, C., Charteris, D.G., Wong, D., Khaw, P.T., Aylward, G.W. Ophthalmology (2001) [Pubmed]
  7. Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. Findlay, M., Hill, A., Cunningham, D., Norman, A., Nicolson, M., Ford, H., Husband, J., Evans, C., Carter, R. Ann. Oncol. (1994) [Pubmed]
  8. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. Miller, B.H., Shavin, J.S., Cognetta, A., Taylor, R.J., Salasche, S., Korey, A., Orenberg, E.K. J. Am. Acad. Dermatol. (1997) [Pubmed]
  9. "Organic brain syndrome" secondary to 5-fluorouracil toxicity. Lynch, H.T., Droszcz, C.P., Albano, W.A., Lynch, J.F. Dis. Colon Rectum (1981) [Pubmed]
  10. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K., Butler, J.S., Hinshaw, J.C., Garnier, P., Prestwich, G.D., Leonardson, A., Garrett-Engele, P., Rush, C.M., Bard, M., Schimmack, G., Phillips, J.W., Roberts, C.J., Shoemaker, D.D. Cell (2004) [Pubmed]
  11. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. Watanabe, T., Wu, T.T., Catalano, P.J., Ueki, T., Satriano, R., Haller, D.G., Benson, A.B., Hamilton, S.R. N. Engl. J. Med. (2001) [Pubmed]
  12. Clinical response to fluorouracil and p53. Augenlicht, L.H., Wadler, S., Arango, D. N. Engl. J. Med. (2001) [Pubmed]
  13. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J., Maroun, J.A., Ackland, S.P., Locker, P.K., Pirotta, N., Elfring, G.L., Miller, L.L. N. Engl. J. Med. (2000) [Pubmed]
  14. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. Speyer, J.L., Green, M.D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A. N. Engl. J. Med. (1988) [Pubmed]
  15. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. Kemeny, N., Huang, Y., Cohen, A.M., Shi, W., Conti, J.A., Brennan, M.F., Bertino, J.R., Turnbull, A.D., Sullivan, D., Stockman, J., Blumgart, L.H., Fong, Y. N. Engl. J. Med. (1999) [Pubmed]
  16. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. O'Connell, M.J., Martenson, J.A., Wieand, H.S., Krook, J.E., Macdonald, J.S., Haller, D.G., Mayer, R.J., Gunderson, L.L., Rich, T.A. N. Engl. J. Med. (1994) [Pubmed]
  17. Treatment of primary breast cancer with chemotherapy and tamoxifen. Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E.R., Plotkin, D., Bowman, D., Sachs, S., Wolter, J., Frelick, R., Desser, R., LiCalzi, N., Geggie, P., Campbell, T., Elias, E.G., Prager, D., Koontz, P., Volk, H., Dimitrov, N., Gardner, B., Lerner, H., Shibata, H. N. Engl. J. Med. (1981) [Pubmed]
  18. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. Ahmann, D.L., O'Connell, M.J., Hahn, R.G., Bisel, H.F., Lee, R.A., Edmonson, J.H. N. Engl. J. Med. (1977) [Pubmed]
  19. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Hwang, P.M., Bunz, F., Yu, J., Rago, C., Chan, T.A., Murphy, M.P., Kelso, G.F., Smith, R.A., Kinzler, K.W., Vogelstein, B. Nat. Med. (2001) [Pubmed]
  20. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Aas, T., Børresen, A.L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J.E., Akslen, L.A., Lønning, P.E. Nat. Med. (1996) [Pubmed]
  21. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. Sasaki, Y., Ohtsu, A., Shimada, Y., Ono, K., Saijo, N. J. Natl. Cancer Inst. (1994) [Pubmed]
  22. Role of administration route in the therapeutic efficacy of doxifluridine. Trave, F., Canobbio, L., Au, J.L., Rustum, Y.M. J. Natl. Cancer Inst. (1987) [Pubmed]
  23. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium. Zsebo, K.M., Wypych, J., McNiece, I.K., Lu, H.S., Smith, K.A., Karkare, S.B., Sachdev, R.K., Yuschenkoff, V.N., Birkett, N.C., Williams, L.R. Cell (1990) [Pubmed]
  24. Effective surgical adjuvant therapy for high-risk rectal carcinoma. Krook, J.E., Moertel, C.G., Gunderson, L.L., Wieand, H.S., Collins, R.T., Beart, R.W., Kubista, T.P., Poon, M.A., Meyers, W.C., Mailliard, J.A. N. Engl. J. Med. (1991) [Pubmed]
  25. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. Moertel, C.G., Lefkopoulo, M., Lipsitz, S., Hahn, R.G., Klaassen, D. N. Engl. J. Med. (1992) [Pubmed]
  26. Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a pre-CFU-S cell? Hodgson, G.S., Bradley, T.R. Nature (1979) [Pubmed]
  27. Letter: Fluorouracil and the blood-brain barrier. Gorshein, D. JAMA (1976) [Pubmed]
  28. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. Brizel, D.M., Albers, M.E., Fisher, S.R., Scher, R.L., Richtsmeier, W.J., Hars, V., George, S.L., Huang, A.T., Prosnitz, L.R. N. Engl. J. Med. (1998) [Pubmed]
  29. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. Muss, H.B., Thor, A.D., Berry, D.A., Kute, T., Liu, E.T., Koerner, F., Cirrincione, C.T., Budman, D.R., Wood, W.C., Barcos, M. N. Engl. J. Med. (1994) [Pubmed]
  30. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. Moertel, C.G., Hanley, J.A., Johnson, L.A. N. Engl. J. Med. (1980) [Pubmed]
  31. Tritiated thymidine labeling index and response in human breast cancer. Sulkes, A., Livingston, R.B., Murphy, W.K. J. Natl. Cancer Inst. (1979) [Pubmed]
  32. Multi-colony stimulating activity of interleukin 5 (IL-5) on hematopoietic progenitors from transgenic mice that express IL-5 receptor alpha subunit constitutively. Takagi, M., Hara, T., Ichihara, M., Takatsu, K., Miyajima, A. J. Exp. Med. (1995) [Pubmed]
  33. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. Stoehlmacher, J., Park, D.J., Zhang, W., Groshen, S., Tsao-Wei, D.D., Yu, M.C., Lenz, H.J. J. Natl. Cancer Inst. (2002) [Pubmed]
  34. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. Ponomaryov, T., Peled, A., Petit, I., Taichman, R.S., Habler, L., Sandbank, J., Arenzana-Seisdedos, F., Magerus, A., Caruz, A., Fujii, N., Nagler, A., Lahav, M., Szyper-Kravitz, M., Zipori, D., Lapidot, T. J. Clin. Invest. (2000) [Pubmed]
  35. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Wang, T.L., Diaz, L.A., Romans, K., Bardelli, A., Saha, S., Galizia, G., Choti, M., Donehower, R., Parmigiani, G., Shih, I.e.M., Iacobuzio-Donahue, C., Kinzler, K.W., Vogelstein, B., Lengauer, C., Velculescu, V.E. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  36. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. LeCouter, J., Zlot, C., Tejada, M., Peale, F., Ferrara, N. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  37. Carcinoma of the anal canal. Ryan, D.P., Compton, C.C., Mayer, R.J. N. Engl. J. Med. (2000) [Pubmed]
  38. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D.D., Kirn, D.H. Nat. Med. (1997) [Pubmed]
  39. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. Cooper, J.S., Guo, M.D., Herskovic, A., Macdonald, J.S., Martenson, J.A., Al-Sarraf, M., Byhardt, R., Russell, A.H., Beitler, J.J., Spencer, S., Asbell, S.O., Graham, M.V., Leichman, L.L. JAMA (1999) [Pubmed]
WikiGenes - Universities